市場調查報告書

全球卡波西氏肉瘤市場:成長,趨勢,及預測

Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 922000
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球卡波西氏肉瘤市場:成長,趨勢,及預測 Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

本報告提供全球卡波西氏肉瘤市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各類型·產品·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • HIV相關的卡波西氏肉瘤發生率增加
    • 接受器官移植的患者數量增加
  • 市場阻礙因素
    • 卡波西氏肉瘤治療和診斷的高成本
    • 由於廣泛的供需缺口,藥品供不應求
  • 波特的五力分析

第5章 市場區隔

  • 各類型
    • 流行性(愛滋病相關)卡波西氏肉瘤
    • 古典型(地中海)卡波西氏肉瘤
    • 地方型(非洲)卡波西氏肉瘤
    • 醫源性(與移植相關的)卡波西氏肉瘤
  • 各產品
    • 各診斷
    • 不同治療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Merck & Co., Inc.
    • Celgene Corporation
    • Eli Lilly and Company
    • Navidea Biopharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb
    • Pfizer Inc.

第7章 市場機會及今後趨勢

目錄
Product Code: 67475

Market Overview

The growing prevalence of the Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible for Kaposi sarcoma, are the major factor attributing the growth of the Kaposi sarcoma market. According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017. Where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, the promising number of pipeline studies, growing incidence of HIV-associated Kaposi sarcoma is also a major factor driving Kaposi sarcoma market. However, a shortage in supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment and diagnosis of Kaposi sarcoma will impede the growth of the market studied globally.

Scope of the Report

As per the American Cancer Society, "Kaposi sarcoma (KS) is cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but these tumors can also develop in other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract". KS is caused by a virus called human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpes virus (KSHV).

Key Market Trends

Highly Active Antiretroviral Therapy (HAART) Segment Holds Significant Market Share

  • Kaposi sarcoma (KS) is common cancer associated with the HIV infection and it is considered as an AIDS-defining condition by the US Centers for Disease Control Guidelines.
  • Numerous advancements in the treatment of AIDS-related Kaposi sarcoma have been attained over the last few years, but the introduction of highly active antiretroviral therapy (HAART) has declined the incidences of AIDS-defining illnesses, including KS.
  • For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV/AIDS is generally used prior to any other therapies for treating the tumor and to reduce the symptoms. HAART might be given as individual therapy or in the combination with chemotherapy depending on the spread of the disease and the patient's symptoms.
  • Seldom, HAART might worsen the condition of the Kaposi sarcoma and the pre-existing infections which leads to a condition called immune reconstitution inflammatory syndrome (IRIS).

North America holds the Largest Market Share in Global Kaposi Sarcoma Market

North America region holds a major market share in the Kaposi treatment market globally. Major factors contributing to this position are the increasing number of product approvals, the presence of many numbers of market players in the market, a high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also bolstering the market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma.

Competitive Landscape

Kaposi Sarcoma market has rapidly progressed over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, in May 2019, The USFDA granted breakthrough therapy designation to Celgene's pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Incidence of HIV-Associated Kaposi Sarcoma
    • 4.2.2 Rising Number of Patients Undergoing Organ Transplantation Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Cost Of The Treatment And Diagnosis Of Kaposi Sarcoma
    • 4.3.2 Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Epidemic (AIDS-associated) Kaposi sarcoma
    • 5.1.2 Classic (Mediterranean) Kaposi sarcoma
    • 5.1.3 Endemic (African) Kaposi sarcoma
    • 5.1.4 Latrogenic (transplant-related) Kaposi sarcoma
  • 5.2 By Product
    • 5.2.1 By Diagnostics
      • 5.2.1.1 Biopsy
      • 5.2.1.2 Bronchoscopy
      • 5.2.1.3 Gastrointestinal endoscopy
      • 5.2.1.4 Others
    • 5.2.2 By Treatment
      • 5.2.2.1 Highly Active Antiretroviral Therapy (HAART)
      • 5.2.2.2 Radiation Therapy
      • 5.2.2.3 Chemotherapy
      • 5.2.2.4 Immunotherapy
      • 5.2.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc.
    • 6.1.2 Celgene Corporation
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Navidea Biopharmaceuticals, Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Bristol-Myers Squibb
    • 6.1.7 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS